The haemophilia A and B markets in the Asia-Pacific (APAC) region are forecast to expand from $444.9 million and $76.3 million in 2015 to $699.1 million and $112.9 million by 2022, representing compound annual growth rates of 6.7% and 5.8%, respectively, according to business intelligence provider GBI Research
The company’s latest report states that the growing awareness of haemophilia and associated risk factors, together with the availability of free testing services for new and existing haemophilia A and B patients, will increase diagnosis, driving demand and contributing to APAC market growth.
Gayathri Kanika, analyst for GBI Research, notes: “One of the most pressing unmet needs in the haemophilia space is for a treatment to address inhibitor development, particularly in those with haemophilia B. The late-stage pipeline contains promising long-acting replacement therapies and non-factor therapies that have the potential for approval and launch during the forecast period.”
The most important driver of growth in the APAC haemophilia A and B markets will be the transition from short-acting to costly long-acting replacement therapies, such as Novo Nordisk’s N9-GP and CSL-Behring’s CSL-689. These products are expected to be launched in the forecast period and capture significant market share, as they require fewer injections and have convenient routes of administration.
In addition to new drugs and rising haemophilia diagnoses, increasing affordability and healthcare access in India and China are likely to contribute to the growth of the treatment-receiving pool significantly.
Kanika explains: “Currently, the diagnosis and treatment rates of haemophilia A and B in India and China, which account for the majority of the prevalence population in APAC, are far lower than the diagnosis and treatment rates in Australia, Japan and South Korea because of to low disease awareness among the public. However, some pharma companies, including Baxalta and Novo Nordisk, have created haemophilia awareness initiatives in India.
“In 2016, the National Hemophilia Co-operative Group in China initiated a project that covers 43 haemophilia treatment centres and provides free testing services for new and old haemophiliacs, helping more than 6000 people with haemophilia.”